Pediatric Acute Myeloid Leukemia: Unraveling Complexities in Intensive Chemotherapy and the Emergence of Superbugs – A Case Study
Sandip Patil,Xinye Li,Huirong Mai,Ying Wang,Xue Tang,Sixi Liu,Feiqiu Wen
DOI: https://doi.org/10.2147/idr.s478065
2024-10-10
Infection and Drug Resistance
Abstract:Sandip Patil, Xinye Li, Huirong Mai, Ying Wang, Xue Tang, Sixi Liu, Feiqiu Wen Department of Haematology and Oncology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, People's Republic of China Correspondence: Sixi Liu; Feiqiu Wen, Email ; Background: This case report underscores the intricate challenges in managing paediatric patients with acute myeloid leukaemia (AML) undergoing intensive chemotherapy, particularly when complicated by the emergence of multidrug-resistant pathogens such as Carbapenem-Resistant Pseudomonas aeruginosa (CRPA). Case Presentation: An 11-year-old male with AML presented with skin purpura and persistent cough. Clinical and laboratory assessments revealed a high-risk AML profile with genetic mutations, leading to the initiation of intensive chemotherapy per the C-HUANA-AML-2015 protocol. Despite successful disease remission after initial chemotherapy courses, the patient experienced unexpected complications. Notably, septic shock, bone marrow failure, and the emergence of CRPA were encountered during the clinical course. Septic shock occurred following Course B3 chemotherapy, marked by a fever unresponsive to initial antibiotic therapy. Despite negative blood cultures, meropenem and vancomycin were initiated, successfully normalizing temperature. Subsequent challenges included persistent bone marrow suppression, perianal dermatitis, and the identification of CRPA in stool cultures, leading to altered antibiotic therapy guided by minimum inhibitory concentration (MIC) considerations. Whole-genome sequencing (WGS) of the CRPA strain revealed a highly virulent clone (ST-970) with numerous resistance and virulence genes. Conclusion: This case report offers new insights into the complexities of pediatric AML management, with a focus on the emergence of CRPA. The discovery of a high-risk CRPA clone with detailed genomic data underscores the growing challenge of antimicrobial resistance in pediatric oncology. The persistent presence of CRPA and ongoing bone marrow failure highlight the difficulties in managing these complications. This case calls for a reassessment of treatment strategies and encourages further research to improve outcomes in pediatric AML, emphasizing the need for a multidisciplinary approach to address infectious complications and antimicrobial resistance. Keywords: acute myeloid leukaemia, carbapenem-resistant Pseudomonas aeruginosa , paediatric oncology, antimicrobial resistance, superbugs Acute myeloid leukaemia poses a significant global challenge, particularly in the concern of paediatric oncology. 1 Managing this condition requires a delicate equilibrium between achieving disease remission and mitigating the risk of opportunistic infections during intensive chemotherapy. 2 The complexity is heightened by the rise of multidrug-resistant pathogens, such as Carbapenem-Resistant Pseudomonas aeruginosa (CRPA), commonly referred to as superbugs. 3 These pathogens introduce additional layers of difficulty in AML treatment, necessitating innovative strategies to address these evolving challenges in pediatric patients. AML is a life-threatening malignancy, characterized by the uncontrolled proliferation of abnormal myeloid progenitor cells in the bone marrow, and predominantly affects children. 4 Intensive chemotherapy has emerged as a pivotal component of AML treatment, leading to improved remission rates. 5 But its success is frequently accompanied by severe complications, notably infections. This issue is further exacerbated by the increasing prevalence of antibiotic-resistant pathogens, especially in pediatric oncology. 6 The several studies underscores the increasing prevalence of multidrug-resistant organisms in paediatric oncology, necessitating a nuanced understanding of their impact on treatment outcomes. 7 CRPA, a common nosocomial pathogen, poses a particular threat to immunocompromised pediatric patients undergoing chemotherapy, as it exhibits resistance to many conventional antibiotics. 4 Despite this issue, there is a notable scarcity of comprehensive case reports exploring the intricate interplay between AML, intensive chemotherapy, and the emergence of CRPA. 8 This case report seeks to expand current knowledge by examining the clinical course of an AML patient who initially achieved disease remission but subsequently faced septic shock, bone marrow failure, and the emergence of CRPA. The challenges encountered in managing this case highlight the shifting landscape of infectious complications in pediatric oncology, prompting a reevaluation of current treatment strategies. By incorporating Whole-Genome Sequencing (WGS) data, this report also aims to shed light on the -Abstract Truncated-
pharmacology & pharmacy,infectious diseases